文献速递心血管CT

秋水仙碱治疗与急性冠脉综合征患者斑块稳定:一项冠状动脉CT血管造影研究

Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study.
PubMed 文献 · JACC Cardiovasc Imaging · 2017-10-18

前瞻性非随机观察性研究纳入80例近期急性冠脉综合征(<1个月)患者,分别接受秋水仙碱0.5 mg/日联合最佳药物治疗或单用最佳药物治疗,随访1年。秋水仙碱组低衰减斑块体积较高敏C反应蛋白降低更明显,总斑块体积和低密度脂蛋白变化两组相当;作者认为低剂量秋水仙碱可能通过抗炎作用有利地修饰冠状动脉斑块。

要点

  • 低剂量秋水仙碱(0.5 mg/日)联合最佳药物治疗可显著降低低衰减斑块体积(LAPV)。
  • LAPV变化与hsCRP变化呈显著线性关联且强正相关(r=0.578),提示抗炎机制。
  • 总斑块体积和低密度脂蛋白降低两组相当,斑块改善独立于他汀强化和LDL降低。

核心结论

  • 研究发现低剂量秋水仙碱治疗有利地修饰冠状动脉斑块,独立于高强度他汀强化治疗和低密度脂蛋白大幅降低;斑块形态改善可能由秋水仙碱的抗炎特性驱动(以hsCRP降低为证),而非脂蛋白变化;作者认为若在未来研究中得到验证,秋水仙碱可能作为ACS后患者的额外二级预防药物。

研究设计与样本

  • 前瞻性非随机观察性研究,纳入80例近期ACS(<1个月)患者,分为秋水仙碱0.5 mg/日联合最佳药物治疗组或最佳药物治疗组,随访1年;主要结局为冠状动脉CTA上低衰减斑块体积(LAPV)变化,次要结局为其他冠状动脉CTA指标和高敏C反应蛋白(hsCRP)变化。

关键影像表现/征象

  • 秋水仙碱组LAPV平均降低15.9 mm3(-40.9%),对照组平均降低6.6 mm3(-17.0%),差异p=0.008。
  • 秋水仙碱组hsCRP平均降低1.10 mg/l(-37.3%),对照组平均降低0.38 mg/l(-14.6%),差异p<0.001。
  • 总动脉粥样硬化体积变化两组相当:秋水仙碱组平均42.3 mm3 vs 对照组平均26.4 mm3,p=0.28。
  • 低密度脂蛋白变化两组相当:秋水仙碱组平均0.44 mmol/l vs 对照组平均0.49 mmol/l,p=0.21。

诊断标准与关键数值

  • 主要结局低衰减斑块体积(LAPV)为冠状动脉CTA上斑块不稳定性标志物及不良心血管事件的强预测因子。
  • 多变量线性回归显示秋水仙碱治疗与LAPV更大降低显著相关(p=0.039)。
  • 多变量线性回归显示秋水仙碱治疗与hsCRP更大降低显著相关(p=0.004)。
  • LAPV变化与hsCRP变化呈显著线性关联(p<0.001)且强正相关(r=0.578)。

临床应用与阅片要点

  • 在ACS后患者中,冠状动脉CTA可用于评估低衰减斑块体积变化以反映斑块稳定性。
  • 低剂量秋水仙碱(0.5 mg/日)联合最佳药物治疗可能作为ACS后额外二级预防策略,但作者指出需在未来研究中验证。

局限性

  • 本研究为前瞻性非随机观察性研究,作者结论中提出秋水仙碱可能有益需在未来研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The authors sought to evaluate the plaque-modifying effects of low-dose colchicine therapy plus optimal medical therapy (OMT) in patients post-acute coronary syndrome (ACS), as assessed by coronary computed tomography angiography (coronary CTA).

BACKGROUND: Colchicine therapy has been postulated to have beneficial anti-inflammatory effects in patients with ACS, translating into reduction in future adverse cardiovascular events. However, whether favorable plaque modification underpins this is yet unproven.

METHODS: In this prospective nonrandomized observational study of 80 patients with recent ACS (<1 month), patients received either 0.5 mg/day colchicine plus OMT or OMT alone and were followed for 1 year. Our primary outcome was change in low attenuation plaque volume (LAPV), a marker of plaque instability on coronary CTA and robust predictor of adverse cardiovascular events. Secondary outcomes were changes in other coronary CTA measures and in high-sensitivity C-reactive protein (hsCRP).

RESULTS: Mean duration of follow-up was 12.6 months; mean age was 57.4 years. Colchicine therapy significantly reduced LAPV (mean 15.9 mm3 [-40.9%] vs. 6.6 mm3 [-17.0%]; p = 0.008) and hsCRP (mean 1.10 mg/l [-37.3%] vs. 0.38 mg/l [-14.6%]; p < 0.001) versus controls. Reductions in total atheroma volume (mean 42.3 mm3 vs. 26.4 mm3; p = 0.28) and low-density lipoprotein levels (mean 0.44 mmol/l vs. 0.49 mmol/l; p = 0.21) were comparable in both groups. With multivariate linear regression, colchicine therapy remained significantly associated with greater reduction in LAPV (p = 0.039) and hsCRP (p = 0.004). There was also a significant linear association (p < 0.001) and strong positive correlation (r = 0.578) between change in LAPV and hsCRP.

CONCLUSIONS: Our findings suggest, for the first time, that low-dose colchicine therapy favorably modifies coronary plaque, independent of high-dose statin intensification therapy and substantial low-density lipoprotein reduction. The improvements in plaque morphology are likely driven by the anti-inflammatory properties of colchicine, as demonstrated by reductions in hsCRP, rather than changes in lipoproteins. Colchicine may be beneficial as an additional secondary prevention agent in patients post-ACS if validated in future studies.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Vaidya K, Arnott C, Martínez GJ, et al. Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study. JACC Cardiovasc Imaging. 2017. PMID: 29055633. doi:10.1016/j.jcmg.2017.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。